Lactobacillus sakei proBio65

Phase 2Small molecule

UUniversity of Illinois at Chicago

Lactobacillus sakei proBio65 is one of 42 small molecule programs targeting Sinusitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SinusitisActive, not recruiting

SinusitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

94 competitors in Sinusitis

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Xylocaine

Rayos

Marcaine

Naropin

FFresenius Kabi Oncology Ltd.

Advil

Asmanex

3 8

Biaxin

AbbVie

Phase 3

1 9

Flovent

GSK

Phase 3

1 10

Avelox

Bayer

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Recruiting

Sinusitis

NCT05427695

Clinical

Trials by Indication[1]

Sinusitis1 trial

Topical Probiotic Sinus Irrigations for Treating Chronic Sinusitis

Recruiting·UUniversity of Illinois at Chicago·Phase 2·NCT05427695·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Lactobacillus sakei proBio65. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lactobacillus sakei proBio65 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lactobacillus sakei proBio65. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Illinois at Chicago company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Illinois at Chicago

Lactobacillus sakei proBio65

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Sinusitis1 trial

References

Drug Info

Quick Facts

Related News